ArticleBMC gastroenterology2025
The potential of lymphocyte-C-reactive protein ratio upon admission to predict therapeutic responsiveness to mesalazine in adult patients with mild-to-moderate active ulcerative colitis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveThis study aimed to investigate the potential of lymphocyte-to-C-reactive protein ratio (LCR) upon admission to predict therapeutic responsiveness to mesalazine in adult patients with mild-to-moderate active ulcerative colitis (UC).
methodsThis single-center cohort study retrospectively recruited adult patients with mild-to-moderate active UC who received mesalazine monotherapy as first-line treatment and underwent the first lower digestive endoscopy within 7 days after admission. Multiple demographic characteristics and clinical indicators were extracted, collated, and calculated from the medical records. Based on their therapeutic responsiveness to mesalazine, the enrolled patients were classified into the therapeutic responsiveness to mesalazine group and the therapeutic non-responsiveness to mesalazine group, respectively. All the aforementioned data were compared between different groups.
resultsA total of 244 adult patients with mild-to-moderate active UC were recruited and subsequently stratified into the therapeutic responsiveness to mesalazine group (n = 165) and the therapeutic non-responsiveness to mesalazine group (n = 79). The overall therapeutic responsiveness to mesalazine in adult patients with mild-to-moderate active UC was 67.62%. LCR upon admission exhibited a significant positive correlation with disease duration and remarkable negative correlations with disease severity as well as the first ulcerative colitis endoscopic index of severity (UCEIS) and Mayo endoscopic score (MES) within 7 days after admission. Disease duration, neutrophil percentage (NEUT%), and LCR upon admission were determined as protective factors for therapeutic responsiveness to mesalazine, whereas disease severity, the first UCEIS within 7 days after admission, and length of hospital stay were identified as risk factors. The areas under the receiver operating characteristic (ROC) curves (AUCs) of disease duration, disease severity, NEUT%, LCR, UCEIS, length of hospital stay, and combination of disease duration, disease severity, NEUT%, LCR, UCEIS, and length of hospital stay were 0.614, 0.818, 0.637, 0.907, 0.800, 0.738, and 0.938, respectively.
conclusionLCR upon admission holds significant potential to predict therapeutic responsiveness to mesalazine in adult patients with mild-to-moderate active UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.